Patent · US Active

High purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and process for the synthesis thereof

US8314145B2 · kind B2 · utility

1Cited by
4References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 11, 2006
Grant dateNov 20, 2012
Priority date
Expiry dateNov 25, 2029

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P15/18
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to a new process for the synthesis of high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents. According to our invention the dienogest of formula (I) is synthesized the following way: i) 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) is reacted with aluminum isopropylate in the presence of cyclohexanone in an inert organic solvent under heating; ii) the so obtained 3-methoxy-estra-2,5(10)-diene-17-one of formula (IV) is reacted with cyanomethyl lithium at a temperature between 0 and −30…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.